Cargando…
The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E‐transformed cells
Metabolic reprogramming, as exemplified by the shift from oxidative phosphorylation to glycolysis, is a common feature of transformed cells. In many tumors, altered metabolism is also reflected in increased reactive oxygen species (ROS) levels, which contribute to proliferation and survival signalin...
Autores principales: | Furlan, Tobias, Khalid, Sana, Nguyen, Anh‐Vu, Günther, Julia, Troppmair, Jakob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983121/ https://www.ncbi.nlm.nih.gov/pubmed/29624862 http://dx.doi.org/10.1002/1878-0261.12199 |
Ejemplares similares
-
Novel Insights into the PKCβ-dependent Regulation of the Oxidoreductase p66Shc
por: Haller, Martina, et al.
Publicado: (2016) -
Rigosertib-Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation
por: Günther, Julia K., et al.
Publicado: (2020) -
cJun N-terminal kinase (JNK) phosphorylation of serine 36 is critical for p66Shc activation
por: Khalid, Sana, et al.
Publicado: (2016) -
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021) -
Kinase Suppressor of RAS 1 (KSR1) Maintains the Transformed Phenotype of BRAFV600E Mutant Human Melanoma Cells
por: Liu, Zhi, et al.
Publicado: (2023)